Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00860496 | A Phase I Open-Label Study of the Effects of Tacrolimus and Cyclosporine on CP-690,555 in Healthy Volunteers | PHASE1 | COMPLETED | 24 | — | — | Jun 1, 2009 | Aug 1, 2009 | Aug 13, 2009 | 1 | Singapore |
| Arm | Type | Description |
|---|---|---|
| 1 | OTHER | Treatment Arm 1 will receive one single dose of CP-690,550 on Day 1, Tacrolimus on Days 1-8, and one single dose of CP-690,550 on Day 8. |
| 2 | OTHER | Treatment Arm 2 will receive one single dose of CP-690,550 on Day 1, Cyclosporine on Days 1-6, and one single dose of CP-690,550 on Day 6. |
| Name | Type | Description |
|---|---|---|
| CP- 690,550 and Tacrolimus | DRUG | 10 mg, single dose of CP-690,550 on Day 1 5 mg, every 12 hours of Tacrolimus on Days 1-8 10 mg, single dose of CP-690,550 on Day 8 |
| CP- 690,550 and Cyclosporine | DRUG | 10 mg, single dose of CP-690,550 on Day 1 200 mg, every 12 hours of Cyclosporine on Days 1-6 10 mg, single dose of CP-690,550 on Day 6 |
Inclusion Criteria: * Healthy males between 21 and 55 years, inclusive. * Healthy females of non-childbearing potential between 21 and 55 years, inclusive. * Total body weight greater than 132 pounds. Exclusion Criteria: * Evidence or history of clinically significant disease * Females of childbe...